Biblio
Advances in pharmacotherapy for myelofibrosis: what is the current state of play?. Expert Opin Pharmacother. 2024.
. RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA. Hematol Oncol. 2020.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2020.
ABCG2, Cytogenetic and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission. Biol Blood Marrow Transplant. 2016.
.